SLC2A1 and neoplasm: This study systematically assessed the in vivo performance of a GLUT1‐targeting boron carrier based on glucose through biodistribution studies in CAL 27 and UT‐SCC‐14 tumor xenografts, aiming to evaluate its potential as an alternative boron carrier for BNCT.